Saphenous Vein Graft Intervention Complications: Difference between revisions
New page: {{SI}} {{CMG}} {{EJ}} As with all medical procedures, complications for SVG intervention can occur. Risk factors for complications include: older graft age (>3-5 years), the pr... |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
As with all medical procedures, complications for [[SVG]] intervention can occur. Risk factors for complications include: older [[graft]] age (>3-5 years), the presence of [[thrombus]], and diffuse disease. | As with all medical procedures, complications for [[SVG]] intervention can occur. Risk factors for complications include: older [[graft]] age (>3-5 years), the presence of [[thrombus]], and diffuse disease. | ||
| Line 11: | Line 11: | ||
As mentioned above, prevention of [[no reflow]] should be attempted with [[embolic]] protection devices, pretreatment using [[nitroprusside]] and the avoidance of high-pressure inflations and unnecessary pre/post-dilation and oversizing. However, in the event that [[no reflow]] develops, it should be aggressively managed with intracoronary [[vasodilators]] (i.e. [[diltiazem]], [[nicardipine]], [[adenosine]], and [[nitroprusside]]). | As mentioned above, prevention of [[no reflow]] should be attempted with [[embolic]] protection devices, pretreatment using [[nitroprusside]] and the avoidance of high-pressure inflations and unnecessary pre/post-dilation and oversizing. However, in the event that [[no reflow]] develops, it should be aggressively managed with intracoronary [[vasodilators]] (i.e. [[diltiazem]], [[nicardipine]], [[adenosine]], and [[nitroprusside]]). | ||
{{ | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 15:52, 20 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
As with all medical procedures, complications for SVG intervention can occur. Risk factors for complications include: older graft age (>3-5 years), the presence of thrombus, and diffuse disease.
Although PCI with stenting is effective for focal lesions, there is uncertainty regarding the best treatment for diffusely degenerated SVGs. In these cases, it is often a better choice to abandon the graft and intervene on the native vessel instead.
As mentioned above, prevention of no reflow should be attempted with embolic protection devices, pretreatment using nitroprusside and the avoidance of high-pressure inflations and unnecessary pre/post-dilation and oversizing. However, in the event that no reflow develops, it should be aggressively managed with intracoronary vasodilators (i.e. diltiazem, nicardipine, adenosine, and nitroprusside).